FierceBiotechOriginal article
{"a":[{"_":"GSK catches phase 3 fever after mRNA flu vaccine beats standard shots","$":{"href":"/biotech/gsk-catches-phase-3-fever-after-mrna-flu-vaccine-beats-standard-shots","hreflang":"en"}}]}
Phase 3mRNA seasonal flu vaccinePositive
AI Analysis
Summary
GSK's mRNA seasonal flu vaccine demonstrated superior immune responses compared to conventional vaccines in phase 2 trials, prompting the company to initiate a pivotal phase 3 study this month.
Clinical Trial Data
Phase
Phase 2/3
Primary Endpoint
Met
Outcome Details
Phase 2 trial showed higher immune responses than conventional flu vaccines; pivotal phase 3 study starting this month
Importance:7/10
Sentiment:
0.80
mRNAflu vaccinephase 2 positivephase 3 initiationimmunogenicity
Related Companies
Read the original article
Published by FierceBiotech on September 1, 2026 5:43 AM